Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Fulcrum Therapeutics, Inc. Common Stock (FULC)

Pharmaceutical Preparations

https://www.fulcrumtx.com

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

26 LANDSDOWNE STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/18/2019

Market Cap

587,191,528

Shares Outstanding

61,820,000

Weighted SO

61,822,554

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

RAPT --.--%

MIRM --.--%

BYSI --.--%

STOK --.--%

PHAT --.--%

Beta

2.2810

Last Div

0.0000

Range

3.14-13.7

Chg

-0.2800

Avg Vol

875587

Mkt Cap

587191528

Exch

NASDAQ

Country

US

Phone

617 651 8851

DCF Diff

9.3461

DCF

0.0333

Div Yield

0.0000

P/S

7.1933

EV Multiple

-16.5330

P/FV

2.1379

Div Yield %

0.0000

P/E

-28.9290

PEG

-0.8945

Payout

0.0000

Current Ratio

22.0715

Quick Ratio

22.0715

Cash Ratio

6.8275

DSO

15.8019

DIO

0.0000

Op Cycle

15.8019

DPO

693.2485

CCC

-677.4466

Gross Margin

0.9769

Op Margin

-0.4015

Pretax Margin

-0.2479

Net Margin

-0.2479

Eff Tax Rate

-0.1979

ROA

-0.0688

ROE

-0.0828

ROCE

-0.1164

NI/EBT

1.0000

EBT/EBIT

0.6174

EBIT/Rev

-0.4015

Debt Ratio

0.0328

D/E

0.0353

LT Debt/Cap

0.0269

Total Debt/Cap

0.0341

Int Coverage

-10.3682

CF/Debt

-1.2898

Equity Multi

1.0748

Rec Turnover

23.0985

Pay Turnover

0.5265

Inv Turnover

0.0000

FA Turnover

7.5829

Asset Turnover

0.2774

OCF/Share

-0.2001

FCF/Share

-0.2029

Cash/Share

4.4012

OCF/Sales

-0.1525

FCF/OCF

1.0137

CF Coverage

-1.2898

ST Coverage

-5.9793

CapEx Coverage

-73.2294

Div&CapEx Cov

-73.2294

P/BV

2.1379

P/B

2.1379

P/S

7.1933

P/E

-28.9290

P/FCF

-46.5323

P/OCF

-47.0198

P/CF

-47.0198

PEG

-0.8945

P/S

7.1933

EV Multiple

-16.5330

P/FV

2.1379

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 07, 16:30 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 10, 16:30 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Oct 31, 08:50 Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

Revenue Product Segmentation